Table 3. Post-induction chemotherapy management and outcomes in patients with brain invasion and neurological deficit.
| Brain invasion cohort | Neurologic deficit cohort | |
|---|---|---|
| Post-induction chemotherapy treatment | 34/40 (85%) | 28/31 (90.3%) |
| Simultaneous CRT | 28 (70.0%) | 21/31 (67.7%) |
| Chemotherapy | 31 (77.5%) | 23/31 (74.2%) |
| Radiation | 30 (75.0%) (Avg: 66.3 Gy) | 25/31 (80.6%) (Avg: 61.1 Gy) |
| Post-induction chemotherapy surgery | 18/40 (45.0%)_ | 11/31 (35.5%) |
| Indication | ||
| Poor or no response to IC | 5/18 (27.8%) | 7/11 (63.6%) |
| Residual disease after IC | 10/18 (55.6%) | 3/11 (27.3%) |
| Recurrent disease after IC and CRT | 3/18 (16.7%) | 1/11 (9.10%) |
| Surgical approach | ||
| Transcranial | 3/18 (16.7%) | 3/11 (27.3%) |
| Transcranial + transfacial | 4/18 (22.2%) | 2/11 (18.2%) |
| Transcranial + endoscopic | 6/18 (33.3%) | 3/11 (27.3%) |
| Endoscopic | 4/18 (22.2%) | 1/11 (9.10%) |
| transfacial | 1/18 (5.60%) | 2/11 (18.2%) |
| Extent of resection | ||
| Gross total resection | 16/18 (88.9%) | 10/11 (90.9%) |
| Negative margins | 13/18 (72.2%) | 9/11 (81.8%) |
| Long-term disease control outcomes | ||
| Recurrence | 16/40 (40.0%) | 16/31 (51.6%) |
| PFS (mo) | 24.8 (SD: 27.4) | 25.9 (SD: 32.9) |
| OS (mo) | 55.7 (SD: 47.3) | 34.9 (SD: 38.2) |
Abbreviations: CRT, chemoradiation therapy; IC, induction chemotherapy; PFS, progression-free survival; OS, overall survival; SD, standard deviation.